DESIGN FEATURES OF ISYCATH ALLOW FOR A UNIQUE COMBINATION OF FUNCTIONALITY

Creation of isolated area in gastrointestinal tract

Controlled negative or positive pressure in isolated area

Delivery of diagnostic or medical products into isolated area

+

Drainage of parts of gastrointestinal tract proximal and distal to isolated area

All this while maintaining connectivity and function of gastrointestinal tract

IsyCath

Enables selective collection of highly specific diagnostic material (e.g. bile, pancreatic juice) for research and diagnostic use

Efficiently evacuates biofluids and contents from an isolated area of gastrointestinal tract, thus helping to prevent and treat acute inflammatory and perforating conditions

Allows for gastric drainage and decompression along with provision of enteral and liquid per-oral nutrition, while simultaneously performing negative pressure therapy in an isolated area of gastrointestinal tract

IsyCath in comparison with alternative diagnostic and treatment tools:

Atraumatic

Easy to use, easy to repeat procedure

Independent of anatomic variants

Does not require specialist centers and expertise

Does not cause complications: pancreatitis, bleeding, tumor dissemination

Allows patient mobility during the procedure of collecting biological samples of tissues and fluids

Long-term usage of the catheter: from several hours to several days

No other device currently on the market creates isolated area in gastrointestinal tract and controlled environment in isolated area while maintaining GI connectivity and function.

EXAMPLES OF POTENTIAL TREATMENT APPLICATIONS OF ISYCATH

Treatment of acute pancreatitis (AP)

Prevention of acute pancreatitis caused by endoscopic removal of gallstones complicated by choledocholithiasis

Treatment of cholangitis

Treatment of fistulas and other perforations of gastrointestinal tract

IN TREATMENT AND PREVENTION OF COMPLICATIONS OF ACUTE PANCREATITIS ISYCATH OFFERS A COMBINATION OF THREE POTENTIALLY EFFECTIVE MECHANISMS OF ACTION: GASTRIC DRAINAGE AND DECOMPRESSION, RESTORATION AND STIMULATION OF THE FUNCTION OF DUODENUM AND INTESTINE, AND FINALLY IMPROVEMENT OF THE OUTFLOW OF PANCREATIC FLUID

TREARMENT OBJECTIVES IsyCath-ENABLED SOLUTION
TREARMENT OBJECTIVES To slow down and stop autolysis of pancreas. To prevent the spread of pancreatitis into not yet affected parts of the organ. IsyCath-ENABLED SOLUTION By creating physiological negative pressure near the duodenal papilla IsyCath effectively emulates normal peristatic function of duodenum, lost in acute pancreatitis, and performs aspiration of pancreatic fluid and duodenal contents, thus improving the outflow of pancreatic fluid and preventing reflux into bile and pancreatic ducts.
TREARMENT OBJECTIVES Reduction of intra-abdominal hypertension and prevention of vomiting and pulmonary complications. IsyCath-ENABLED SOLUTION IsyCath facilitates gastric drainage and decompression helping to prevent or manage intra-abdominal hypertension (IAH) and development of abdominal compartment syndrome (ACS) –severe complications of acute pancreatitis often leading to multiple organ dysfunction syndrome (MODS). Further, this helps to prevent vomiting and potential pulmonary complications.
TREARMENT OBJECTIVES Restoration of the normal function of duodenum and intestine and provision of nutritional support. ISYCATH-ENABLED SOLUTION IsyCath enables early and continuous provision of enteral and/or liquid per-oral nutrition, which in addition to supporting patients, stimulates and helps to restore normal function of intestine. This in turn helps to prevent or manage endotoxin and bacterial translocation and development of dangerous complication such as infectious pancreatitis, systemic inflammatory response syndrome (SIRS) and MODS.

While treating fistulas and other perforations of gastrointestinal tract IsyCath enables effective evacuation of the contents from an isolated area, preventing it from miGrating and causing inflammation outside the GI tract, and facilitating the healing of perforations

EXAMPLES OF DIAGNOSTIC APPLICATIONS OF ISYCATH

Early detection of pancreatic cancer in high-risk population

Diagnosis of liver, gallbladder and bile duct cancer in high risk population

Diagnosis and monitoring of treatment effectiveness of viral hepatitis

Functional evaluation of liver and pancreas: biochemical analysis, proteinogram, etc

Bacteriological analysis of bile and pancreatic juice

Diagnostics of autoimmune diseases of liver, bile ducts and pancreas

Drug metabolism evaluation (DMPK) in bile

Targeted evaluation of microbiome in a selected part of gastrointestinal tract isolated by IsyCath

ADVANTAGES OF ISYCATH IN COLLECTING BIOFLUIDS FOR RESEARCH AND TESTING

Analysis of selectively collected of pancreatic juice provides more accurate information about the state of the liver, bile ducts and pancreas

Large volume of biofluids collected (100 ml or more) allows for multiple testing methods and increases their informativeness

IsyCath enables collection of biochemically and physiologically representative material without artificial stimulation and without contamination with gastric and intestinal juices. This allows to avoid dilution and loss of biomarkers and increases informativeness of testing

To partners and investors:

To partners

We are looking for collaboration opportunities with investigators, research and clinical organizations who see the benefits of using IsyCath to address their clinical and research needs, as well as those interested in participating in projects we have initiated:

Urgent surgery

Evaluation of the effectiveness of IsyCath in comparison with standard of care in treating moderate and severe acute pancreatitis

Oncology

Evaluation of the effectiveness of IsyCath-enabled method of collecting biofluids in detection of biomarkers of pancreatic cancer

Gastroenterology

Diagnosis and monitoring of gallstone disease and autoimmune conditions of liver and bile ducts

For more information about the projects contact us at: info@pandica.com

To Investors

We have developed a fully functional device with unique characteristics, which has undergone preliminary clinical evaluation and demonstrated its effectiveness. Patent applications have been made covering the design, functionality and utility of IsyCath in diagnosing and treating diseases of gastrointestinal and hepato-biliary systems, as well as in other therapeutic areas.

Development and validation of treatment and diagnostic methods enabled by IsyCath will result in significant clinical and economic benefits:

Prevent the development of serious complications and reduce mortality rate of patients with moderate and severe acute pancreatitis and other disease of gastrointestinal and hepato-biliary systems

Reduced the overall length of stay and length of stay in intensive care units for patients

Considerably reduced cost of treating patients with moderate and severe acute pancreatitis and overall burden of treating acute diseases of gastrointestinal and hepato-biliary systems

En Инвесторам 4

Improved early disease detection, accuracy of diagnosis and better outcomes for patients with oncological and non-oncological conditions of hepato-biliary and gastrointestinal systems

ACUTE PANCREATITIS ALONE is estimated to CAUSE over 2.5 MILLION HOSPITALIZATIONS PER YEAR ACROSS THE GLOBE

AT THE MOMENT, GLOBAL DEMAND FOR early detection of ONLY ONCOLOGICAL conditions of HEPATOBILIARY ZONE IS over 7 MILLION tests PER YEAR

If you are interested in exploring and developing the potential of IsyCat to diagnose diseases and treat patients, please contact us at: info@pandica.com

Our Team

Aleksei Kashintsev
MD, PhD – practicing physician and clinical leader of the project. More than 10 years in pancreatic surgery
Vitali Proutski
DPhil (Oxon) – expert in biomarker panels discovery and development. Senior manager, scientific and technical leader with international experience in biopharmaceutical and diagnostics R&D and commercial services in the UK, Netherlands and USA
Sergei Anisimov
MD, PhD, operating director. Extensive scientific experience and expertise in cell biology in the USA, Sweden and Russia. Sergey has Hirsch Index = 24 with 3500 citations. Working as a project leader Sergey dealt with various types of Macroarrays, e.g: NIA15K (USA) and NeuroStem (Sweden)
Oleg Granstrem
PhD, director of business development. Oleg has a rich experience in developing large scientific projects in pharmaceutical and diagnostic companies, such as rolling out laboratory of neurochemistry (Oasi Maria Institute for Research on Mental Retardation and Brain Aging, Italy)

Contacts

E-mail: info@pandica.com
Phone: +7-921-594-65-32
Address: 194100, 36H lit.A Litovskaya Street, Saint-Petersburg, Russia